New inhibitors of p38 kinase

Bibliography

• LEE JC, LAYDON JT, MCDONNELL PC et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739–746.
   PubMed Web of Science ®Google Scholar
• ••The discovery of the molecular target for the4 (5)-aryl-5 (4)-pyridyl-imidazole anti-inflammatory agents.
   Google Scholar
• HANSON GJ: Inhibitors of p38 kinase. Exp. Opin. Ther. Patents (1997) 7(7):729–733.
   Web of Science ®Google Scholar
• ••This is the first review of p38 inhibitors which covers thepatent literature. It covers patents on p38 inhibitors through March 1997.
   Google Scholar
• LANTOS I, BENDER PE, RAZGAITIS KA et al.: Anti-inflammatory activity of 5,6-diary1-2,3- dihydro-imidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted phenyl derivatives. J. Med. Chem. (1984) 27:72–75.
   Google Scholar
• •This was the first paper describing the anti-inflammatory properties of 4-aryl-5-pyridyl imidazoles. The reasoning behind the design of the drugs was explained. A remarkably accurate binding hypothesis was proposed.
   Google Scholar
• LEE JC, GRISWOLD DE, VOTTA B et al: Inhibition of monocyte IL-1 production by the anti-inflammatory compound SK&F 86002. Int. J. Immunopharm. (1988) 10:835–843.
   PubMed Web of Science ®Google Scholar
• HAN J, LEE J-D, BIBBS RJ, ULEVITCH RJ: An MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science (1994) 265:808–811.
   PubMed Web of Science ®Google Scholar
• LEE JC, KASSIS S, KUMAR S, BADGER A, ADAMS JL: p38 mitogen-activated protein kinase inhibitors mechanisms and therapeutic potentials. Pharmacol. Ther. (1999) 82(2-3):389–397.
   PubMed Web of Science ®Google Scholar
• DE LASZLO SE, VISCO D, AGARWAL L et al.: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorganic & Med. Chem. Lett. (1998) 8:2689–2694.
   PubMed Web of Science ®Google Scholar
• BADGER AM, ADAMS JL: New treatments for arthritis. In: Annual Reports in Medicinal Chemistry (1998) 33:203–212.
   Google Scholar
• ADAMS JL, LEE D: Recent progress towards the identifi- cation of selective inhibitors of serine/threonine protein kinases. Curr. Opin. Drug Dis. Dev. 1999 2(2): 96–109.
   PubMed Web of Science ®Google Scholar
• •Review of serine/threonine protein kinase inhibitors including a thorough review of recent patent literature on p38 kinase inhibitors.
   Google Scholar
• YOUNG PR: Pharmacological modulation of cytokine action and production through signaling pathways. Cytokine Growth Factor Rev. (1998) 9(3/4):239–257.
   Google Scholar
• SALIRURO FG, GERMANN UA, WILSON KP et al.: Inhibi-tors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Cur. Med. Chem. (1999) 6:807–823.
   PubMedGoogle Scholar
• POULIOT M, BAILLARGEON J, LEE JC, CLELAND LG, JAMES MJ Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-activated protein kinase. j Immunol. (1997) 158:4930–4937.
   PubMed Web of Science ®Google Scholar
• BADGER AM, COOK MN, LARK MW et al.: SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol (1998) 161:467–473.
   PubMed Web of Science ®Google Scholar
• LEE JC, BADGER AM, GRISWOLD DE et al.: Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors. Ann. NY Acad. Sci. (1993) 696:149–170.
   PubMed Web of Science ®Google Scholar
• GALLAGHER TF, FIER-THOMPSON SM, GARIGAPATI RS et 2,4,5-Triarylimidazole inhibitors of IL-1 biosyn-thesis. Bioorg & Med Chem Lett (1995) 5:1171–1176.
   Web of Science ®Google Scholar
• BOEHM JC, SMIETANA JM, SORENSON ME et al.: 1-Substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem. (1996) 39:3929–3937.
   PubMed Web of Science ®Google Scholar
• NEWTON RC, DECICCO CP: Therapeutic potential and strategies for inhibiting tumor necrosis factor-a. J. Med. Chem. (1999) 42:2295–2314.
   PubMed Web of Science ®Google Scholar
• GALLAGHER TF, SEIBEL GL, KASSIS S et al: Regulation of stress-induced cytokine production by pyridinylimi-dazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. (1997) 5(0:49–64.
   PubMedGoogle Scholar
• LIVERTON NJ, BUTCHER JW, CLAIRBORNE CF et al.: Design and synthesis of potent, selective, and orally bioavailable tetrasubstitued imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. (1999) 42:2180–2190.
   PubMed Web of Science ®Google Scholar
• ADAMS JL, BOEHM JC, KASSIS S et al.: Pyrimidinylimida-zole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome p450 enzymes. Bioorg. & Med. Chem. Lett. (1998) 8:3111–3116.
   PubMed Web of Science ®Google Scholar
• HENRY JR, RUPERT JH, DOOD JH et al.: Potent inhibitors of the MAP kinase p38 Bioorg. Med. Chem. Lett. (1998) 8:3335–3340.
   PubMed Web of Science ®Google Scholar
• HENRY JR, RUPERT KC, DODD JH et al.: 6-Amino-2-(fluoropheny1)-methoxy-3-(4-pyridy1)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor. J. Med. Chem. (1998) 41:4196–4198.
   PubMed Web of Science ®Google Scholar
• YOUNG PR, MC GLAUGHLIN ME, KUMAR S et al.: Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. (1997) 272(18):12116–12121.
   PubMedGoogle Scholar
• TONG L, PAV S, WHITE DM et al.: A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. (1997) 4(4): 311–316.
   PubMedGoogle Scholar
• WILSON KP, MCCAFFREY PG, HSIAO K et al.: The structural basis for the specificity of pyridinylimida-zole inhibitors of p38 kinase. Chem. Biol. (1997) 4:423–431.
   PubMedGoogle Scholar
• WANG Z., CANAGARAJAH BJ, BOEHM JC et al. Structural basis of inhibitor selectivity in MAP kinases. Structure (London) (1998) 6(9):1117–1128.
   PubMed Web of Science ®Google Scholar
• GUM RJ, MCLAUGHLIN MM., KUMAR S et al: Acquisitionof sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J. Biol. Chem. (1998) 273(25):15605–15610.
   PubMedGoogle Scholar
• EYERS PA, CRAXTON M, MORRICE N, COHEN P, GOEDERT M: Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. (1998) 5:321–328.
   PubMedGoogle Scholar
• LISNOCK JM, TEBBEN A, FRANTZ B: Molecular basis forp38 protein kinase inhibitor specificity. Biochem. (1998) 37(47):16573–16581.
   PubMedGoogle Scholar
• TESTA B, JENNER P: Inhibitors of cytochrome P-450sand their mechanism of action. Drug Metab. Rev. (1981) 12:1.
   PubMed Web of Science ®Google Scholar
• KIM SG, NOVAK RF: The induction of cytochrome P4502E1 by nitrogen- and sulfur- containing heterocy-cles: expression and molecular regulation. Toxicol. Appl. Pharmacol (1993) 120:257.
   PubMedGoogle Scholar
• GALLAGHER TF, BOEHM JC, OSIFO IK et al: Aminopy-rimidinylimidazoles as inhibitors of p38 kinase (CSW') . American Chemical Society. 215th National Meeting, Dallas USA (March 29 to April 2 1998). Book of Abstracts.
   Google Scholar
• SISKO J, MELLINGER M, SHELDRAKE PW, BAINE NH: Anefficient method for the synthesis of substituted TosMIC precursors. Tetrahedron Lett. (1996) 37(45):8113–8116.
   Google Scholar
• SISKO J: A one-pot synthesis of 1-(2,2,6,6-tetramethyl-4-piperidiny0-imidazole: a potent inhibitor of p38 MAP kinase. J. Org. Chem. (1998) 63:4529–4531.
   Web of Science ®Google Scholar
• AAES A, GRISWOLD DE, SKAK-NIELSEN T et al.: Topical anti-inflammatory activity of 11EP689 in 3 murine models of atopic dermatitis. Mediators Inflamm. (1999) 8:Suppl. 1-11-11.
   Google Scholar
• LEO PHARMACEUTICALS PRODUCTS LTD: Drug develop-ment pipeline: tinzaparin, GS-1590, EB-1089, CHS-828, P-1075, EO-1428, HEP-688, HEP-689. Company Communication (1999) July 13. (IDdb reference report)
   Google Scholar
• BADGER AM, BRADBEER JN, VOTTA B et al: Pharma-cological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, Endotoxin shock, and immune function J. Pharmacol. Exp. Ther. (1996) 279:1453–1461.
   PubMed Web of Science ®Google Scholar
• MCLAY I, COLLIS A, SOUNESS J, RATCLIFFE A, MILLER G,JAYYASI Z: RPR200765A. Discovery of a novel p38 Inhibitor. American Chemical Society 218th National Meeting. New Orleans, LA, USA (August 22–26 1999).
   Google Scholar
• MCLAY IM, COLLIS A, HALLEY F: The discovery ofRPR200765A: a novel inhibitor of p38 MAP kinase. 10th RSC-SCI Med. Chem. Symp. Cambridge (September 1999).
   Google Scholar
• Two novel structural classes of p38 kinase inhibitors.Exp. Opin. Ther. Patents (1999) 9(4):477–480.
   Google Scholar
• Substituted pyrazoles as p38 kinase inhibitors. Exp. Opin. Ther. Patents (1999) 9(7):975–979.
   Google Scholar
• HENRY JR, DODD JH: Synthesis of RJW 68354: a potent inhibitor of the MAP kinase p38. Tetrahedron Lett. (1998) 39:8763–8764.
   Web of Science ®Google Scholar
• Vertex Press Release. News Wire (8 July 1998).
   Google Scholar
• Vertex Press Release. News Wire (2 November 1999).
   Google Scholar
• SU M: Kinase. FASEB meeting. (August 1999).
   Google Scholar
• SALITURO F: P38 Inhibitors. TNF Second International Meeting: A Validated Target with Multiple Therapeutic Potential. Princeton, NJ, USA 24–25 February 1999. IDdb Meeting Report.
   Google Scholar
• MOHAMMADI M, MCMAHON G, SUN L et al.: Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (1997) 276:955–960.
   PubMed Web of Science ®Google Scholar
• HALL-JACKSON CA, EYERS PA, COHEN P et al.:Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. (1999) 6:559–568.
   PubMed Web of Science ®Google Scholar